Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Junghun | - |
dc.contributor.author | Kim, Hwan | - |
dc.contributor.author | Yu, Hana | - |
dc.contributor.author | Chung, Jae Yoon | - |
dc.contributor.author | Oh, Chang-Hyun | - |
dc.contributor.author | Yoo, Kyung Ho | - |
dc.contributor.author | Sim, Taebo | - |
dc.contributor.author | Hah, Jung-Mi | - |
dc.date.accessioned | 2021-06-23T13:37:44Z | - |
dc.date.available | 2021-06-23T13:37:44Z | - |
dc.date.issued | 2010-03 | - |
dc.identifier.issn | 0960-894X | - |
dc.identifier.issn | 1464-3405 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/39934 | - |
dc.description.abstract | The synthesis of a novel series of pyrimidin-4-yl-1H-imidazol-2-yl derivatives 7, 8, 9 and their antiproliferative activities against A375P human melanoma cell line and WM3629 cell line were described. Most compounds showed superior antiproliferative activities compared to Sorafenib, the well-known RAF inhibitor. Among them, 7a exhibited potent activities on both cell lines (IC50 = 0.62 and 4.49 mu M, respectively) and turned out to be a selective and potent CRAF inhibitor. (C) 2010 Elsevier Ltd. All rights reserved. | - |
dc.format.extent | 5 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.title | Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1016/j.bmcl.2010.01.064 | - |
dc.identifier.scopusid | 2-s2.0-76649090272 | - |
dc.identifier.wosid | 000274714600023 | - |
dc.identifier.bibliographicCitation | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, v.20, no.5, pp 1573 - 1577 | - |
dc.citation.title | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | - |
dc.citation.volume | 20 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 1573 | - |
dc.citation.endPage | 1577 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Organic | - |
dc.subject.keywordPlus | MALIGNANT-MELANOMA | - |
dc.subject.keywordPlus | BRAF | - |
dc.subject.keywordPlus | KINASE | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | CRAF | - |
dc.subject.keywordPlus | SORAFENIB | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | RAF | - |
dc.subject.keywordPlus | ERK | - |
dc.subject.keywordAuthor | Pyrimidin-4-yl-1H-imidazol-2-yl derivatives | - |
dc.subject.keywordAuthor | Antiproliferative activity | - |
dc.subject.keywordAuthor | Melanoma cell line | - |
dc.subject.keywordAuthor | BRAF | - |
dc.subject.keywordAuthor | CRAF | - |
dc.subject.keywordAuthor | Selectivity | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0960894X10000764?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.